Antibody-Drug Conjugates in Oncology: From Bench to Bedside - K. Y. Chen - 20250122

Antibody drug conjugates have seen a rise in use for the treatment of many different types of cancer. These agents possess a unique mechanism of action different than our prior cancer-directed therapies. Kevin Chen, PharmD, MS, BCOP, CPP, will dive deeper into their structure and pharmacology, key landmark trials highlighting their benefit, and current toxicity challenges limiting their potential, with the goal for attendees to better understand these novel therapeutic agents and incorporate them into their practice.